Simulations Plus (NASDAQ:SLP) Updates FY 2026 Earnings Guidance

Simulations Plus (NASDAQ:SLP) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided earnings per share guidance of 1.030-1.100 for the period, compared to the consensus earnings per share estimate of 1.000. The company issued revenue guidance of $79.0 million-$82.0 million, compared to the consensus revenue estimate of $80.5 million.

Simulations Plus Trading Down 4.6%

Shares of Simulations Plus stock opened at $16.89 on Friday. The firm has a fifty day simple moving average of $19.04 and a 200-day simple moving average of $16.47. The stock has a market capitalization of $340.33 million, a price-to-earnings ratio of -5.28 and a beta of 1.09. Simulations Plus has a 1-year low of $12.39 and a 1-year high of $37.67.

Simulations Plus (NASDAQ:SLP) last released its earnings results on Thursday, January 8th. The technology company reported $0.13 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.05). Simulations Plus had a negative net margin of 81.66% and a positive return on equity of 14.02%. The business had revenue of $18.42 million during the quarter, compared to analyst estimates of $18.05 million. During the same period last year, the business earned $0.17 EPS. As a group, research analysts predict that Simulations Plus will post 1.09 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on SLP shares. Zacks Research raised Simulations Plus from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 28th. BTIG Research lowered shares of Simulations Plus from a “buy” rating to a “neutral” rating in a research report on Thursday, December 18th. KeyCorp reaffirmed a “sector weight” rating on shares of Simulations Plus in a research note on Wednesday, October 29th. Citigroup reiterated a “market perform” rating on shares of Simulations Plus in a research note on Tuesday, January 6th. Finally, TD Cowen reissued a “hold” rating on shares of Simulations Plus in a research note on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $25.00.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. First Light Asset Management LLC bought a new stake in shares of Simulations Plus during the second quarter worth approximately $6,232,000. Squarepoint Ops LLC grew its holdings in Simulations Plus by 522.1% during the 3rd quarter. Squarepoint Ops LLC now owns 220,103 shares of the technology company’s stock worth $3,317,000 after acquiring an additional 184,725 shares during the period. Ameriprise Financial Inc. raised its position in shares of Simulations Plus by 25.3% during the 2nd quarter. Ameriprise Financial Inc. now owns 875,447 shares of the technology company’s stock valued at $15,277,000 after acquiring an additional 176,747 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Simulations Plus by 76.7% in the 3rd quarter. Bank of America Corp DE now owns 369,585 shares of the technology company’s stock valued at $5,570,000 after purchasing an additional 160,367 shares during the period. Finally, Marshall Wace LLP lifted its stake in shares of Simulations Plus by 435.9% in the 2nd quarter. Marshall Wace LLP now owns 133,278 shares of the technology company’s stock valued at $2,326,000 after purchasing an additional 108,407 shares during the period. Institutional investors own 78.08% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.